Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor

ZUSAMMENFASSUNG

Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (erenumab) or against CGRP (eptinezumab, fremanezumab, galcanezumab) are new substances for the preventive treatment of migraine. They represent an extension of the therapeutic options which already exist in migraine prevention. In registration studies, the efficacy and good tolerability of these specific substances have been demonstrated in patients with episodic and chronic migraine. The following treatment recommendation presents a summary of the pivotal studies. Recommendations are given for the targeted selection of patients as well as for the evaluation of therapeutic success and the duration of treatment. Finally, possible restrictions in the use of this new substance group are discussed.

ABSTRACT

Monoklonale Antikörper gegen den Calcitonin Gene-Related Peptide (CGRP)-Rezeptor (Erenumab) oder gegen CGRP (Eptinezumab, Fremanezumab, Galcanezumab) sind neue Substanzen zur prophylaktischen Behandlung der Migräne. Sie stellen eine Erweiterung der therapeutischen Optionen in der Migräneprophylaxe dar. In Zulassungsstudien wurden die Wirksamkeit und die gute Verträglichkeit dieser spezifischen Substanzen bei Patienten mit episodischer und chronischer Migräne nachgewiesen. Die folgende Empfehlung präsentiert eine Zusammenfassung der Daten aus den Zulassungsstudien. Weiterhin werden Empfehlungen zur gezielten Patientenauswahl sowie zur Beurteilung des Therapieerfolgs und der Dauer der Behandlung gegeben. Abschließend werden mögliche Anwendungseinschränkungen für diese neue Substanzgruppe diskutiert.

• Literatur

• 1 American Headache Society The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache 2019; 59 (01) 1-18
• 2 Kosinski M, Bayliss MS, Bjorner JB. et al A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 2003; 12 (08) 963-74
• 3 Diener H-C, Gaul C, Kropp P. et al Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie. https://www.dgn.org/leitlinien Deutsche Gesellschaft für Neurologie; Berlin: 2018
• 4 Tassorelli C, Diener HC, Dodick DW. et al Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia 2018: 333102418758283
• 5 Berger A, Bloudek LM, Varon SF. et al Adherence with migraine prophylaxis in clinical practice. Pain Pract 2012; 12 (07) 541-9
• 6 Goadsby PJ, Edvinsson L. Sumatriptan reverses the changes in calcitonin gene-related peptide seen in the headache phase of migraine. Cephalalgia 1991; 11 (Suppl. 11) 3-4
• 7 Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33 (01) 48-56
• 8 Eftekhari S, Salvatore CA, Calamari A. et al Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 2010; 169 (02) 683-96
• 9 Edvinsson L, Villalon CM, Maassen Van Den Brink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther 2012; 136 (03) 319-33
• 10 Edvinsson L, Goadsby PJ, Olesen IL. et al CGRP, CGRP mRNA and CGRP1 receptor mRNA and release from the human trigeminovascular system. In Poyner D, Marshall I, Brain S. editors The CGRP Family: Calcitonin Gene-Related Peptide (CGRP), Amylin, and Adrenomedullin. Georgetown, Texas: Landes Bioscience; 2000: 167-71
• 11 McCulloch J, Uddman R, Kingman TA. et al Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A 1986; 83 (15) 5731-5
• 12 Edvinsson L, Haanes KA, Warfvinge K. et al CGRP as the target of new migraine therapies – successful translation from bench to clinic. Nat Rev Neurol 2018; 14 (06) 338-50
• 13 Olesen J, Diener HC, Husstedt IW. et al Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. The New England Journal of Medicine 2004; 350 (11) 1104-10
• 14 Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 2019; 394 10210 1765-74
• 15 Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Headache 2019; 59 (Suppl. 02) 20-32
• 16 Diener H, Gaul C. Erenumab. Drug Report 2018; 12 (19) 1-17
• 17 Goadsby PJ, Reuter U, Hallstrom Y. et al A Controlled Trial of Erenumab for Episodic Migraine. The New England Journal of Medicine 2017; 377 (22) 2123-32
• 18 Dodick DW, Ashina M, Brandes JL. et al ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018; 38 (06) 1026-37
• 19 Reuter U, Goadsby J, Lanteri-Minet M. et al Efficacy and safety of erenumab in episodic migraine patients with 2–4 prior preventive treatment failures: results from the phase 3b LIBERTY study. Migraine Trust International Symposium 2018 September, 2018
• 20 Reuter U, Goadsby PJ, Lanteri-Minet M. et al Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018; 392 10161 2280-7
• 21 Dodick DW, Silberstein SD, Bigal ME. et al Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. Jama 2018; 319 (19) 1999-2008
• 22 Stauffer VL, Dodick DW, Zhang Q. et al Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 2018; 75 (09) 1080-8
• 23 Skljarevski V, Matharu M, Millen BA. et al Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38 (08) 1442-54
• 24 Rosen N, Pearlman E, Ruff D. et al 100 % Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies. Headache 2018; 58 (09) 1347-57
• 25 Tepper SJ. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache 2018; (Suppl. 58) 03: 276-90
• 26 Aurora SK, Dodick DW, Turkel CC. et al OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia : an international journal of headache 2010; 30 (07) 793-803
• 27 Diener HC, Dodick DW, Aurora SK. et al OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30 (07) 804-14
• 28 Dodick DW, Turkel CC, DeGryse RE. et al OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50 (06) 921-36
• 29 Silberstein SD, Blumenfeld AM, Cady RK. et al OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013; 331 1–2 48-56
• 30 Diener HC, Bussone G, Van Oene JC. et al Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27 (07) 814-23
• 31 Diener HC, Dodick DW, Goadsby PJ. et al Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia 2009; 29 (10) 1021-7
• 32 Diener HC, Bussone G, Van Oene JC. et al Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27 (07) 814-23
• 33 Silberstein S, Lipton R, Dodick D. et al Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 2009; 49 (08) 1153-62
• 34 Tepper S, Ashina M, Reuter U. et al Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology 2017; 16 (06) 425-34
• 35 Silberstein SD, Dodick DW, Bigal ME. et al Fremanezumab for the Preventive Treatment of Chronic Migraine. The New England Journal of medicine 2017; 377 (22) 2113-22
• 36 Detke HC, Goadsby PJ, Wang S. et al Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018; 91 (24) e2211-e21
• 37 Dodick DW, Lipton RB, Silberstein S. et al Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia 2019; 39 (09) 1075-85
• 38 Ruff DD, Ford JH, Tockhorn-Heidenreich A. et al Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. Cephalalgia 2019; 39 (08) 931-44
• 39 Sacco S, Bendtsen L, Ashina M. et al European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. The Journal of Headache and Pain 2019; 20 (01) 6
• 40 Reuter U, Goadsby PJ, Lanteri-Minet M. et al Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 2018; 392: 2280-2287
• 41 Ashina M, Tepper S, Brandes JL. et al Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 2018; 38 (10) 1611-21
• 42 Schwedt T, Reuter U, Tepper S. et al Early onset of efficacy with erenumab in patients with episodic and chronic migraine. The Journal of Headache and Pain 2018; 19 (01) 92
• 43 Bigal ME, Dodick DW, Krymchantowski AV. et al TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology 2016; 87 (01) 41-8
• 44 Skljarevski V, Oakes TM, Zhang Q. et al Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol 2018; 75: 187-193
• 45 Cohen JM, Dodick DW, Yang R. et al Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines. Headache 2017; 57 (09) 1375-84
• 46 Bigal ME, Dodick DW, Rapoport AM. et al Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. The Lancet Neurology 2015; 14 (11) 1081-90
• 47 Stauffer VL, Wang S, Voulgaropoulos M. et al Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials. Headache 2019; 59 (06) 834-47
• 48 Raffaelli B, Mussetto V, Israel H. et al Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. The Journal of Headache and Pain 2019; 20 (01) 66
• 49 Ashina M, Dodick D, Goadsby PJ. et al Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology 2017; 89 (12) 1237-43
• 50 Silberstein SD, McAllister P, Ning X. et al Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials. Headache 2019; 59 (06) 880-90
• 51 Depre C, Antalik L, Starling A. et al A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina. Headache 2018; 58 (05) 715-23